On April 20th, 2023, Bill Faloon presented at the HEALinc Summit in the Bahamas and described some challenges currently delaying the development of regenerative medicine, including zealous regulatory overreach.
Bill Faloon at HEALinc Summit April 20th 2023 Perpetual Project Presentationmaximuspeto
On April 20th, 2023, Bill Faloon presented an extensive presentation at the HEALinc Summit about human age-reversal technologies. There, he introduced the new Perpetual Project—an informal association focused on assessing and altering biomarkers with experimental age-reversal technologies to extend the lives of its members.
Bill Faloon on Interventions Designed to Reverse Human Agingmaximuspeto
In his presentation at the HEALinc Summit in April 2023, Bill Faloon describes some interventions designed to reverse human aging. These interventions include senolytics, rapamycin, and NAD+ replenishment among others.
Bill Faloon's 2023 RAADfest Presentation Slidesmaximuspeto
Bill Faloon presented at RAADfest 2023. Topics he emphasized included the delay in translating research findings into routine medical practice, delays and restrictions by the FDA, and advancements in age-reversal since RAADfest 2022.
Bill Faloon's RAADfest 2022 Keynote Presentation slides about Age Reversalmaximuspeto
This is the presentation slides for Bill Faloon's keynote presentation about the prospects for human age reversal, which he presented at RAADfest 2022 on Thursday October 6th.
Bill Faloon on what's delaying regenerative medicine in 2023.pptxmaximuspeto
Bill Faloon describes how excessively restrictive drug testing and approval policies have delayed medical developments that could greatly extend healthy human life. These are presentation slides for a presentation he gave on February 9th, 2023 in West Palm Beach Florida with Jonathan Emord, who is considering running for a Senate seat in the state of Virginia with a focus on reform of drug testing and approval procedures in the United States.
Further to several additional expert workshops this year, we are delighted to share an updated global perspective on the future of healthcare. Produced in partnership with Duke Corporate Education (http://www.dukece.com), this adds new insights on the pivotal shifts taking place across the sector plus viewpoints on some of the core implications for leadership. Topics include the growing power of data; the rising impact of urbanisation on health; increasing patient centricity; the need for more flexible organisations and the move of innovation activity eastwards.
Available as both a report and as this accompanying presentation this is now being used to inform and provoke further debate around the world. As ever we would like to thank all those who have given their time and insight to contribute to this project.
Bill Faloon at HEALinc Summit April 20th 2023 Perpetual Project Presentationmaximuspeto
On April 20th, 2023, Bill Faloon presented an extensive presentation at the HEALinc Summit about human age-reversal technologies. There, he introduced the new Perpetual Project—an informal association focused on assessing and altering biomarkers with experimental age-reversal technologies to extend the lives of its members.
Bill Faloon on Interventions Designed to Reverse Human Agingmaximuspeto
In his presentation at the HEALinc Summit in April 2023, Bill Faloon describes some interventions designed to reverse human aging. These interventions include senolytics, rapamycin, and NAD+ replenishment among others.
Bill Faloon's 2023 RAADfest Presentation Slidesmaximuspeto
Bill Faloon presented at RAADfest 2023. Topics he emphasized included the delay in translating research findings into routine medical practice, delays and restrictions by the FDA, and advancements in age-reversal since RAADfest 2022.
Bill Faloon's RAADfest 2022 Keynote Presentation slides about Age Reversalmaximuspeto
This is the presentation slides for Bill Faloon's keynote presentation about the prospects for human age reversal, which he presented at RAADfest 2022 on Thursday October 6th.
Bill Faloon on what's delaying regenerative medicine in 2023.pptxmaximuspeto
Bill Faloon describes how excessively restrictive drug testing and approval policies have delayed medical developments that could greatly extend healthy human life. These are presentation slides for a presentation he gave on February 9th, 2023 in West Palm Beach Florida with Jonathan Emord, who is considering running for a Senate seat in the state of Virginia with a focus on reform of drug testing and approval procedures in the United States.
Further to several additional expert workshops this year, we are delighted to share an updated global perspective on the future of healthcare. Produced in partnership with Duke Corporate Education (http://www.dukece.com), this adds new insights on the pivotal shifts taking place across the sector plus viewpoints on some of the core implications for leadership. Topics include the growing power of data; the rising impact of urbanisation on health; increasing patient centricity; the need for more flexible organisations and the move of innovation activity eastwards.
Available as both a report and as this accompanying presentation this is now being used to inform and provoke further debate around the world. As ever we would like to thank all those who have given their time and insight to contribute to this project.
Future of Healthcare – Leadership Challenges
Further to several additional expert workshops this year, we are delighted to share an updated global perspective on the future of healthcare. Produced in partnership with Duke Corporate Education (http://www.dukece.com), this adds new insights on the pivotal shifts taking place across the sector plus viewpoints on some of the core implications for leadership. Topics include the growing power of data; the rising impact of urbanisation on health; increasing patient centricity; the need for more flexible organisations and the move of innovation activity eastwards.
Available as both this report and as an accompanying presentation (https://www.slideshare.net/futureagenda2/future-of-healthcare-15-october-2019-182433390) this is now being used to inform and provoke further debate around the world. As ever we would like to thank all those who have given their time and insight to contribute to this project.
ARTIFICIAL ORGANS.
We discussed a Brief History and Introduction of Artificial Organs.
We also discussed the Various Manufacturing Process and Application of Artificial Organs and finally we discussed the Pros and Cons of Artificial Organs.
As the author of “Big Data in Healthcare Hype and Hope,” Dr. Feldman has interviewed over 180 emerging tech and healthcare companies, always asking, “How can your new approach help patients?” Her research shows that data, as an enabling tool, has the power to give us critical new insights into not only what causes disease, but what comprises normal. Despite this promise, few patients have reaped the benefits of personalized medicine. A panel of leading big data innovators will discuss the evolving health data ecosystem and how big data is being leveraged for research, discovery, clinical trials, genomics, and cancer care. Case studies and real-life examples of what’s working, what’s not working, and how we can help speed up progress to get patients the right care at the right time will be explored and debated.
• Bonnie Feldman, DDS, MBA - Chief Growth Officer, @DrBonnie360
• Colin Hill - CEO, GNS Healthcare
• Jonathan Hirsch - Founder & President, Syapse
• Andrew Kasarskis, PhD - Co-Director, Icahn Institute for Genomics & Multiscale Biology; Associate Professor, Genetics & Genomic Studies, Icaahn School of Medicine at Mt. Sinai
• William King - CEO, Zephyr Health
New York eHealth Collaborative Digital Health Conference
November 18, 2014
Precision Medicine is now a funded NIH initiative and an organic movement in the clinic and at the research institute. Based on work with Genomics England, multiple large pharmaceutical firms, and research hospitals, attendees will learn about the best practices for epidemiology, signal detection, research, and the clinical diagnostics associated with Precision Medicine, including the development of high-scale bio-repositories that link traditional patient data with genomic information. Come hear about how leadership, collaboration, consent, and compute can lead to success or failure in your Precision Medicine initiative, and how to bring your stakeholders together for an aligned mission response.
Keynote presentation at Pharma MES Europe (September 26, 2023 in Berlin)
Current status of using Artificial Intelligence and Machine Learning in drug manufacturing. The presentation provides an overview about different AI models, maturity for implementing AI supported software solutions, potential uses cases, and challenges. A recent survey conducted amongst MES solution providers provides an overview about what to expect in the future.
This white paper offers a detailed perspective on how big data is impacting the healthcare industry and its underlying implication on the industry as a whole. It outlines the role of big data in healthcare, its benefits, core components and challenges faced by the healthcare sector towards full-fledged adoption & implementation.
Frailty applications in clinical practice. Assessing level of frailty can help identify underlying risks to contextualize conversations with patients and their caregivers.
By leveraging Big Data, the healthcare industry has an incredible potential to improve lives. This session will give examples of how data volume, velocity and variety is transforming the “art” of a doctor to the science of care. It will describe how the use of machine learning and massive amount of data will drive the new Consumer Drive healthcare movement.
The New Age of Healthcare Ecosystems: Infographic (1)IBM in Healthcare
Learn how ecosystems will change the nature of business activities, expand capabilities and enable experiences in healthcare and life sciences beyond anything possible today.
To know more, visit: ibm.biz/healthecos
MHealth or Mobile Health is an emerging and an innovative of medication in India, by doctors can communicate and treat their patients very conveniently even from far distances.
73What is Special Education 1iStockphotoThinkstock.docxalinainglis
73
What is Special Education? 1
iStockphoto/Thinkstock
Pre-Test
1. You can use the terms disability and handicap interchangeably. T/F
2. The history of special education began in Europe. T/F
3. The first American legislation that protected students with disabilities was passed in the 1950s. T/F
4. All students with disabilities should be educated in special education classrooms. T/F
5. Special education law is constantly reinterpreted. T/F
Answers can be found at the end of the chapter.
4Accreditation, Regulation, and
Agencies of Healthcare Quality
Alex Brandon/AP/Associated Press
Learning Objectives
After reading this chapter, you should be able to do the following:
• Illustrate how healthcare policies, rules and regulations, and guidelines impact quality of care.
• Analyze the role of accreditors, including The Joint Commission, along with major steps in the
accreditation of healthcare organizations.
• Evaluate the role of Leapfrog group on quality of healthcare and the methodology used to compute
the hospital safety score.
• Analyze the structure and process of the National Committee for Quality Assurance (NCQA)
accreditation for health plans.
• Assess the role of several government institutions on the quality of care.
fin81226_04_c04_073-118.indd 73 10/30/14 7:41 PM
Introduction
Introduction
At the turn of the 20th century, there were few federal regulations to protect the public from
dangerous drugs. Many harmful products were freely sold, such as William Radam’s Microbe
Killer and Benjamin Bye’s Soothing Balmy Oils to cure cancer. As is sometimes the case, trag-
edy brought about the first real regulation to protect consumers health and safety. The Bio-
logics Control Act was passed in 1902 after two incidents involving the deaths of children
caused by contaminated vaccines. The law mandated producers in the U.S. to be licensed each
year for the manufacture and sale of biologics such as antitoxins, serum, and vaccines to pre-
vent future tragedies from reoccurring. That was followed by the Pure Food and Drugs Act in
1906, which prohibited interstate commerce in misbranded and adulterated foods, drinks,
and drugs and mandated strict health safety and testing policies. The law was passed mainly
in response to shocking public disclosures of unsanitary conditions in meat packing plants, as
well as fears over poisonous preservatives and dyes in foods.
However, the 1906 law had its shortcomings and the government’s hands were tied when it
came to preventing the sale of medicinal products that carried wild claims of health cures.
In 1910, the government stopped sales of a product called Dr. Johnson’s Mild Combination
Treatment for Cancer, but the Supreme Court ruled in favor of the company because the prod-
uct’s false claims were not within the scope of the Pure Food and Drugs Act (Meadows, 2006).
As a result, in 1912, Congress passed the Sherley Amendment, which prohibited labels on
medicines that fals.
Future of Healthcare – Leadership Challenges
Further to several additional expert workshops this year, we are delighted to share an updated global perspective on the future of healthcare. Produced in partnership with Duke Corporate Education (http://www.dukece.com), this adds new insights on the pivotal shifts taking place across the sector plus viewpoints on some of the core implications for leadership. Topics include the growing power of data; the rising impact of urbanisation on health; increasing patient centricity; the need for more flexible organisations and the move of innovation activity eastwards.
Available as both this report and as an accompanying presentation (https://www.slideshare.net/futureagenda2/future-of-healthcare-15-october-2019-182433390) this is now being used to inform and provoke further debate around the world. As ever we would like to thank all those who have given their time and insight to contribute to this project.
ARTIFICIAL ORGANS.
We discussed a Brief History and Introduction of Artificial Organs.
We also discussed the Various Manufacturing Process and Application of Artificial Organs and finally we discussed the Pros and Cons of Artificial Organs.
As the author of “Big Data in Healthcare Hype and Hope,” Dr. Feldman has interviewed over 180 emerging tech and healthcare companies, always asking, “How can your new approach help patients?” Her research shows that data, as an enabling tool, has the power to give us critical new insights into not only what causes disease, but what comprises normal. Despite this promise, few patients have reaped the benefits of personalized medicine. A panel of leading big data innovators will discuss the evolving health data ecosystem and how big data is being leveraged for research, discovery, clinical trials, genomics, and cancer care. Case studies and real-life examples of what’s working, what’s not working, and how we can help speed up progress to get patients the right care at the right time will be explored and debated.
• Bonnie Feldman, DDS, MBA - Chief Growth Officer, @DrBonnie360
• Colin Hill - CEO, GNS Healthcare
• Jonathan Hirsch - Founder & President, Syapse
• Andrew Kasarskis, PhD - Co-Director, Icahn Institute for Genomics & Multiscale Biology; Associate Professor, Genetics & Genomic Studies, Icaahn School of Medicine at Mt. Sinai
• William King - CEO, Zephyr Health
New York eHealth Collaborative Digital Health Conference
November 18, 2014
Precision Medicine is now a funded NIH initiative and an organic movement in the clinic and at the research institute. Based on work with Genomics England, multiple large pharmaceutical firms, and research hospitals, attendees will learn about the best practices for epidemiology, signal detection, research, and the clinical diagnostics associated with Precision Medicine, including the development of high-scale bio-repositories that link traditional patient data with genomic information. Come hear about how leadership, collaboration, consent, and compute can lead to success or failure in your Precision Medicine initiative, and how to bring your stakeholders together for an aligned mission response.
Keynote presentation at Pharma MES Europe (September 26, 2023 in Berlin)
Current status of using Artificial Intelligence and Machine Learning in drug manufacturing. The presentation provides an overview about different AI models, maturity for implementing AI supported software solutions, potential uses cases, and challenges. A recent survey conducted amongst MES solution providers provides an overview about what to expect in the future.
This white paper offers a detailed perspective on how big data is impacting the healthcare industry and its underlying implication on the industry as a whole. It outlines the role of big data in healthcare, its benefits, core components and challenges faced by the healthcare sector towards full-fledged adoption & implementation.
Frailty applications in clinical practice. Assessing level of frailty can help identify underlying risks to contextualize conversations with patients and their caregivers.
By leveraging Big Data, the healthcare industry has an incredible potential to improve lives. This session will give examples of how data volume, velocity and variety is transforming the “art” of a doctor to the science of care. It will describe how the use of machine learning and massive amount of data will drive the new Consumer Drive healthcare movement.
The New Age of Healthcare Ecosystems: Infographic (1)IBM in Healthcare
Learn how ecosystems will change the nature of business activities, expand capabilities and enable experiences in healthcare and life sciences beyond anything possible today.
To know more, visit: ibm.biz/healthecos
MHealth or Mobile Health is an emerging and an innovative of medication in India, by doctors can communicate and treat their patients very conveniently even from far distances.
73What is Special Education 1iStockphotoThinkstock.docxalinainglis
73
What is Special Education? 1
iStockphoto/Thinkstock
Pre-Test
1. You can use the terms disability and handicap interchangeably. T/F
2. The history of special education began in Europe. T/F
3. The first American legislation that protected students with disabilities was passed in the 1950s. T/F
4. All students with disabilities should be educated in special education classrooms. T/F
5. Special education law is constantly reinterpreted. T/F
Answers can be found at the end of the chapter.
4Accreditation, Regulation, and
Agencies of Healthcare Quality
Alex Brandon/AP/Associated Press
Learning Objectives
After reading this chapter, you should be able to do the following:
• Illustrate how healthcare policies, rules and regulations, and guidelines impact quality of care.
• Analyze the role of accreditors, including The Joint Commission, along with major steps in the
accreditation of healthcare organizations.
• Evaluate the role of Leapfrog group on quality of healthcare and the methodology used to compute
the hospital safety score.
• Analyze the structure and process of the National Committee for Quality Assurance (NCQA)
accreditation for health plans.
• Assess the role of several government institutions on the quality of care.
fin81226_04_c04_073-118.indd 73 10/30/14 7:41 PM
Introduction
Introduction
At the turn of the 20th century, there were few federal regulations to protect the public from
dangerous drugs. Many harmful products were freely sold, such as William Radam’s Microbe
Killer and Benjamin Bye’s Soothing Balmy Oils to cure cancer. As is sometimes the case, trag-
edy brought about the first real regulation to protect consumers health and safety. The Bio-
logics Control Act was passed in 1902 after two incidents involving the deaths of children
caused by contaminated vaccines. The law mandated producers in the U.S. to be licensed each
year for the manufacture and sale of biologics such as antitoxins, serum, and vaccines to pre-
vent future tragedies from reoccurring. That was followed by the Pure Food and Drugs Act in
1906, which prohibited interstate commerce in misbranded and adulterated foods, drinks,
and drugs and mandated strict health safety and testing policies. The law was passed mainly
in response to shocking public disclosures of unsanitary conditions in meat packing plants, as
well as fears over poisonous preservatives and dyes in foods.
However, the 1906 law had its shortcomings and the government’s hands were tied when it
came to preventing the sale of medicinal products that carried wild claims of health cures.
In 1910, the government stopped sales of a product called Dr. Johnson’s Mild Combination
Treatment for Cancer, but the Supreme Court ruled in favor of the company because the prod-
uct’s false claims were not within the scope of the Pure Food and Drugs Act (Meadows, 2006).
As a result, in 1912, Congress passed the Sherley Amendment, which prohibited labels on
medicines that fals.
FDA Regulation of Promotion & Advertising Part 6B: First Amendment, Off-Label...Michael Swit
November 10, 2017 presentation to the ComplianceOnline course on Ensuring Compliance with FDA Regulation of Promotion & Advertising of Drugs and Medical Devices, in Boston.
The Food and Drug Administration (FDA or USFDA) is an agency of the United States Department of Health and Human Services, one of the United States federal executive departments.
The FDA is responsible for protecting and promoting public health through the regulation and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs (medications), vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices (ERED), veterinary products, and cosmetics.
The FDA also enforces other laws, notably Section 361 of the Public Health Service Act and associated regulations, many of which are not directly related to food or drugs.
These include sanitation requirements on interstate travel and control of disease on products ranging from certain household pets to sperm donation for assisted reproduction.
IN THIS SUMMARY
The United States Food and Drug Administration (FDA) has significant reach in the American economy, ranging from medicines and medical devices to items on the grocery store shelves. Since its inception in 1906, the agency has faced a variety of technical and political challenges. Looking ahead, the FDA faces many new demands that could enlarge the agency’s already expansive mandate. New responsibilities may include the cost of medicine, consumers’ pursuit of perfection through drugs, consumer lifestyles, tobacco, and counterterrorism. As the nature of public health changes over time, it is inevitable that the FDA’s scope and responsibilities will change as well. In Inside the FDA, Fran Hawthorne explains the history of the FDA, how its processes work, and what the future may hold for this government agency.
SUBSCRIBE TODAY
http://www.bizsum.com/summaries/inside-fda
FDA Regulation of Promotion & Advertising -- Part 6: First Amendment, Off-La...Michael Swit
Presentation to the Compliance Online 2-day course on Ensuring Compliance with FDA Requirements for the Promotion & Advertising of Drugs and Medical Devices, March 23, 2018
Lab training Logo
Lab training Logo
Home
About US
Courses
Pricing
Blog
Testimonials
Contact Us
Login
Differences between Verification, Calibration and Validation
Dr. Deepak
December 8, 2017
7 Comments
Data Scrutiny is important before reporting
Data Scrutiny is important before reporting
You have perhaps come across these terms in laboratory documents and wondered that they convey the same meaning so where is the need for different terminology.
A little insight will help you understand the fine differences between them. Giving their concise definitions may suffice to gain a basic understanding but to help you get a clearer understanding I have attempted to offer clarity on the terms in context of routine activities in analytical laboratories as I believe that giving real life examples rather than recalling definitions serves the purpose better and makes you remember what is being conveyed longer.
Along with their definitions, I have also pointed out the difference between calibration and validation, and also the difference between calibration and verification. So you will be able to use these terms appropriately.
Let’s first explore what these terms mean:
Verification
In simple terms verification means confirming the authenticity of activities or data before communication to concerned parties. It is important that the results communicated by you are free from errors. Essentially verification comprises of multiple checks on supplies, samples and data before forwarding the results of your testing activities. Majority of the checks can be carried out by you but it is advised that independent assistance be taken for rechecking the data before submission.
Self Checks
The Correct sample was taken up for analysis.
The Sample description, analysis instructions were verified before start of analysis.
The Equipment and glassware used were calibrated.
Recommended grades of chemicals from reliable sources were used.
Weight readings were correctly recorded and entered in calculations.
Recommended environmental conditions were maintained throughout the analysis.
Independent checks
It is strongly recommended that independent rechecking be carried out by a set of trained individuals before the analysis results are consolidated for report generation.
The Sample is analyzed as per the customer’s requirements. As an example in pharmaceutical analysis the tests are conducted in compliance with USP, BP, IP, etc.
If sample information such as name, batch number, date of manufacture, date of expiry, sample source, etc are entered correctly or not in reports.
Entered data matches with the data in the w
Calibration of laboratory instrum
CASE 15 The Diethylstilbestrol Story An Investigation into the Evo.docxwendolynhalbert
CASE 15 The Diethylstilbestrol Story An Investigation into the Evolving Public Health Policy for Pharmaceutical Products
MARGARET ANN MILLER, EMILY BLECKER, AND MEGHAL PATEL
i Regulatory agencies such as the United States Food and Drug Administration (FDA) play an important role in promoting and protecting public health by preventing or limiting exposure to unsafe products. Unfortunately, laws and regulations that protect public health are rarely proactive. Most current laws, regulations, and policies governing the manufacture and sale of pharmaceutical drug products (drugs) were enacted following a public health disaster. Understanding how public health disasters have impacted the development of health laws and regulations is critical for understanding current public health policy in the United States and for developing a proactive, rather than reactive public health framework. This case study describes the tragic story of the prescription drug, diethylstilbestrol (DES). It involves numerous players in the public health arena including research scientists, regulators, pharmaceutical companies, physicians, lawyers, advocates, and of course, patients.
INTRODUCTION
In 1971, several physicians noted an alarming increase in the development of clear cell adenocarcinoma in teenage girls and young women. This rare and potentially deadly form of vaginal and cervical cancer had previously occurred mainly in women over 50 years of age. The only treatment was major invasive surgery to remove the uterus (hysterectomy) or vagina (vaginectomy). This surgery was not only emotionally and physically painful but sometimes not a cure. A few physicians began to search for the cause of this rare form of cancer, and one physician, Arthur Herbst, described a common link: all of the women developing clear cell adenocarcinoma were exposed to DES in utero.1 The implications of this finding were terrifying for the American public—millions of children might develop cancer or some other reproductive problem after an unknown length of time because their mothers took this prescription medication during pregnancy. Today there is still no test for detecting DES exposure and it is impossible to know how many people were, or will be, affected by the medication. DES remains one of the most significant public health disasters of the 20th century.
THE BEGINNING
Starting in the mid-1920s, scientists understood the action of natural estrogens and their potential utility for treating numerous conditions from cancer to wrinkles. The natural estrogens identified at that time were not water soluble and showed no activity when given orally. Several research scientists (many of whom were supported by pharmaceutical companies) began their search for an orally active form of estrogen. In 1938, British physician and chemist Charles Dodds and his team of scientists published a paper describing the synthesis of DES, a compound that showed estrogenic activity when consumed orally in t ...
Dietary Supplements, Combination Products, and Veterinary MedicineMichael Swit
Presentation to the 2015 Regulatory Affairs Certification (RAC) Test Review Course sponsored by the San Diego Regulatory Affairs Network (SDRAN) in July 2017, with a focus on:
A Brief History of Combination Product Regulation
Primary Mode of Action (PMOA) –The Key Lynchpin to FDA’s Regulatory Regime for Combination Products
The Request for Designation (RFD) Process
GMPs
Post-Market Safety Reporting
How Many Applications to File?
User Fees
Regulations for drug approval in USA, E.U & India
Pharmaceutical industry is the most regulated of all the industries. Regulations are put in order to develop the most efficient and safe pharmaceutical products. It takes more than 8 to 15 years to develop a new drug product & costs more than $ 800 million.
Similar to Bill Faloon on What is Delaying Regenerative Medicine in 2023 (20)
Bill Faloon at Healinc Summit, 2024 in The Bahamasmaximuspeto
In this presentation, Bill Faloon highlights the rapid, recent progress on age-reversal research in mice and primates as humanity gets closer to implementing age-reversal technologies into human medicine. These are his slides from his presentation at the Healinc Summit at the Atlantis Hotel in the Bahamas on April 29th, 2024.
Bill Faloon on Age Reversal at Old Fort Bay Club Bahamas 2024maximuspeto
In this presentation, Bill Faloon highlights the rapid, recent progress on age-reversal research in mice and primates as humanity gets closer to implementing age-reversal technologies into human medicine. These are his slides from his presentation at the Old Fort Bay Club in the Bahamas in 2024.
Fruit Fly Combo Treatment Life Extension.pptxmaximuspeto
These three presentation slides by Bill Faloon illustrate the additive effects of multiple life-extension interventions when administered in fruit flies (lithium, rapamycin, and trametinib). This finding suggests that it could be very beneficial to experiment with multi-intervention clinical studies in aging humans.
Clinical trials for human age-reversal therapies are urgently needed because thousands of people are dying from age-related diseases every day. We can petition Congress and the FDA to amend clinical trial constraints to allow for individuals to join clinical trials with adequate informed consent.
Bill Faloon gives update about human age-reversal clinical studiesmaximuspeto
In this presentation, Bill Faloon gives an update on clinical studies aimed and reversing age-related degeneration in humans at the DaVinci 50 Masters Conference in Key Largo, Florida on April 29th, 2021.
Bill Faloon on Anti-Aging Drugs at DaVinci 50 Conference, 2021maximuspeto
In this presentation, Bill Faloon gives an update on the prospects of anti-aging drugs at the DaVinci 50 Masters Conference in Key Largo, Florida on April 29th, 2021.
Bill Faloon Age Reversal Update at DaVinci 50 Masters Conference 2021maximuspeto
In this presentation, Bill Faloon gives an update on the prospects for human age reversal medicine at the DaVinci 50 Masters Conference in Key Largo, Florida on April 29th, 2021.
Bill Faloon at DaVinci 50 about stroke risk and blood pressuremaximuspeto
In this presentation on Thursday April 29th, 2021 at the DaVinci 50 Mastermind Conference in Key Largo, Florida, Bill Faloon discusses how to optimize blood pressure to reduce stroke risk.
Bill Faloon's presentation for Age Reversal webinar on Jan 23rd 2021maximuspeto
Bill Faloon presented an age reversal update on a webinar hosted by the Coalition for Radical Life Extension on January 23rd, 2021. These are his presentation slides.
Age Reversal Update from Bill Faloon on December 15th 2020maximuspeto
Bill Faloon of LifeExtension reviews several recent age-reversal topics including the remarkable effects of hyperbaric oxygen on telomere length and senescence in humans and clinical studies designed to assess age-reversal potential of multiple interventions.
Bill Faloon at Healthy Masters Conference 2020maximuspeto
Bill Faloon explores the recent hyperbaric oxygen study published in the journal Aging, in which the researchers reported a 20% increase in average telomere length in the human study volunteers.
2019.12.08 Bill Faloon at Confidential Cures Summit Dec 8 2019.maximuspeto
Bill Faloon presents some remarkable advancements in human age-reversal medicine at the Confidential Cures Summit in Palm Beach Florida on December 8th, 2019.
2019.12.08 Bill Faloon Healthy Masters Portugalmaximuspeto
Bill Faloon presents on current topics related to human age-reversal, including rapamycin, senolytics, metformin, NAD+, and human clinical trials of some of these compounds.
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Antimicrobial stewardship to prevent antimicrobial resistanceGovindRankawat1
India is among the nations with the highest burden of bacterial infections.
India is one of the largest consumers of antibiotics worldwide.
India carries one of the largest burdens of drug‑resistant pathogens worldwide.
Highest burden of multidrug‑resistant tuberculosis,
Alarmingly high resistance among Gram‑negative and Gram‑positive bacteria even to newer antimicrobials such as carbapenems.
NDM‑1 ( New Delhi Metallo Beta lactamase 1, an enzyme which inactivates majority of Beta lactam antibiotics including carbapenems) was reported in 2008
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
4. GNC Indicted for Promotion of Primrose Oil
Nov. 15th, 1984
https://www.nytimes.com/1984/11/15/us/health-food-company-is-indicted-on-promotion-of-oil-of-primrose.html
Reason: FDA says no studies support safety/efficacy of primrose oil.
Investigation: Criminal investigation initiated in 1980.
FDA threat: GNC executives threatened with 5-year jail sentence.
Outcome: GNC corporation & two executives plead guilty.
GNC stops promoting primrose oil.
7. FDA indicted me in November 1991
Sought prison term of >80 Years
8.
9. FDA Advocates that HIV
Patients Use Dietary Supplements
“There is widespread agreement that nutrition
intervention should begin as soon as a diagnosis is
made. Once people realize they are HIV positive,
they should take steps to improve nutrition…
Healthful eating principles, including
importance of certain nutrients and use
of vitamin and mineral supplements.”
12. April 2015
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382132/
Meta-Analysis Shows Dietary Supplements Slow HIV Progression
“…micronutrient supplementation substantially and significantly reduces the
risk of HIV disease progression by 38% in adults not on anti-viral therapy.”
“adding the mineral selenium improved the outcome
significantly” (disease progression reduced by 64%).
“addition of zinc to a micronutrient supplement reduced mortality (by 71%)”
“The annual cost per patient of micronutrient supplement
reported ranged from about $12 to $40/year.”
13. Lots of Free Publicity Courtesy of FDA Trying to incarcerate Bill Faloon
18. Lethal Delays in Approving Ribavirin
1972 - Anti-viral effects of ribavirin discovered by ICN Pharma
1983 - LifeExtension® recommends ribavirin to its members
1991 - FDAbringscriminalchargesagainstLifeExtension®founders
1995 - FDA brings criminal charges against ICN Pharm founder
1998 - FDA approves ribavirin as lifesaving anti-viral therapy
Tragic Outcome:
https://www.lifeextension.com/magazine/1998/9/wws
60,000 hepatitis C victims die
waiting for ribavirin to be approved.
19. FDA Surrenders in 1996
This was the first time the FDA has been
forced to give up on a criminal prosecution.
https://www.lifeextension.com/magazine/1996/9/freedom
By February 1996, Federal Judge Daniel
Hurley dismissed all 56 criminal charges
against Saul Kent and William Faloon.
This victory goes beyond winning in court.
The FDA's defeat is a victory for everyone
who cherishes freedom in healthcare.
20. FDA Surrenders in 1996
https://www.lifeextension.com/magazine/1996/9/freedom
21. FDA Surrenders in 1996
https://www.lifeextension.com/magazine/1996/9/freedom
22. • Forced FDA to allow health claims
on dietary supplements.
• Forced FDA to accelerate approval of
life saving drugs.
• Stopped FDA from censoring off-label
drug information.
Life Extension Victories Against
FDA in Courts & Congress
23. Dr. Robert Hayling
Florida civil rights leader
Jailed for 6 months for asking to be served at a Woolworth's lunch counter.
Offered plea deals in exchange for promise of no future protests.
Released after appeals by Martin Luther King, Jackie Robinson, others
http://bigstory.ap.org/article/caec64fd3f9e4731bb9c4bdd801c0879/dr-robert-hayling-florida-civil-rights-leader-dies-86
In 1964 Dr. Hayling imprisoned for defying authority:
24. Consecutive Years
of Monthly Publication
(> 400,000 copies mailed each month)
43
1994-2023: Life Extension Magazine
1986-1994: Life Extension Report
1980-1986: Anti-Aging News
25.
26. Perpetual Project Goals
Age-Reversal.Net
Utilize blood & other tests to evaluate safety & potential efficacy.
Robust communications amongst the group members, share test
result data & suggestions on potential ways to improve outcomes.
Accelerate & validate potential rejuvenation technologies to
benefit all of humanity…including Perpetual Project members.
Rapidly convey data to members and the public so that
medical professionals, scientists, and the lay persons are
aware of scientific findings that may save human lives.
27. Join the Perpetual Project private
association and receive updates
about regenerative medicine initiatives
www.age-reversal.net
How to Enroll
29. Island House Hotel
New Providence, The Bahamas
William Faloon
April 20th 2023
The Perpetual Project
Editor's Notes
In about 15 minutes, I am going to make an announcement that is unprecedented in the history of medical science. In fact what is being unveiled right here at RAADfest is unparalleled in the history of the human race.